Company News

GENE-UP^® CAMPYLOBACTER is a real-time PCR-based solution that delivers results in under an hour and is AOAC validated for a variety of enrichment medias.

In May 2024, bioMérieux entered into a strategic partnership with AnaBioTec, an analytical service provider for pharmaceutical, biopharmaceutical and cell-based drugs, from early to late phases of development. Both companies intend to advance and transform Mycoplasma testing for the biopharmaceutical and Cell & Gene Therapy (CGT) industries, in Europe.

bioMérieux inaugurated its new Rodolphe Mérieux Campus on May 31, in Bagno a Ripoli, Italy, in the presence of Alain Mérieux, Chairman of Institut Mérieux, and Pierre Boulud, Chief Executive Officer of bioMérieux. The site comprises of a new R&D center focusing on the fight against Antimicrobial Resistance. This is the result of an investment of €9 million.

bioMérieux co-hosted a conference with the Embassy of France in the United States on May 14 titled, “Rising to the Challenge: United Against Antimicrobial Resistance.” The conference featured renowned speakers from various sectors, including government agencies, academia, and industry, who discussed the latest global policies and initiatives to tackle antimicrobial resistance (AMR). His Excellency Laurent Bili, French Ambassador to the United States and Alexandre Mérieux, bioMérieux Chairman of the Board of Directors, gave opening remarks.

bioMérieux, a world leader in the field of in vitro diagnostics, has received the 2024 Business of the Year Award, presented by the Utah Governor’s Office of Economic Opportunity at One Utah Summit April 11-12, in Salt Lake City.